

## RESULTS OF EXTRAORDINARY GENERAL MEETING

**MELBOURNE (AUSTRALIA) 9 May 2025:** In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions put to shareholders of Invion Limited (ASX: IVX) ("**Invion**") at its Extraordinary General Meeting held earlier today.

This announcement was approved for release by the Company Secretary of Invion Limited.

### Investor and Media enquiries:

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

Brendon Lau (Investor & Media Relations)

M: +61 409 341 613

E: [brendon.lau@inviongroup.com](mailto:brendon.lau@inviongroup.com)

### About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

### About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".

**Invin Limited**  
**Extraordinary General Meeting**  
**Friday, 9 May 2025**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution Details			Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Results
Resolution		Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1a.	Approval of the Issue of Options to Directors - Issue of Options to Mr Thian Chew	Ordinary	6,477,245 95.25%	117,670 1.73%	205,245 3.02%	2,138 -	6,682,490 98.16%	125,592 1.84%	2,138 -	Carried
1b.	Approval of the Issue of Options to Directors - Issue of Options to Mr Alan Yamashita	Ordinary	6,368,603 95.17%	110,855 1.66%	212,060 3.17%	2,138 -	6,580,663 98.23%	118,777 1.77%	2,138 -	Carried
1c.	Approval of the Issue of Options to Directors - Issue of Options to Mr Alistair Bennallack	Ordinary	6,477,245 95.25%	117,670 1.73%	205,245 3.02%	2,138 -	6,682,490 98.16%	125,592 1.84%	2,138 -	Carried
2a.	Ratification of Prior Issue of Shares - Issue of Initial Shares to Lind	Ordinary	6,479,137 96.39%	37,520 0.56%	205,245 3.05%	80,396 -	6,684,382 99.32%	45,442 0.68%	80,396 -	Carried
2b.	Ratification of Prior Issue of Shares - Issue of Options to Lind	Ordinary	6,479,137 96.39%	37,520 0.56%	205,245 3.05%	80,396 -	6,684,382 99.32%	45,442 0.68%	80,396 -	Carried
2c.	Ratification of Prior Issue of Shares - Issue of Shares to Lind (16 October 2024)	Ordinary	6,458,302 96.08%	58,355 0.87%	205,245 3.05%	80,396 -	6,663,547 99.02%	66,277 0.98%	80,396 -	Carried
2d.	Ratification of Prior Issue of Shares - Issue of Shares to Lind (25 November 2024)	Ordinary	6,458,302 96.08%	58,355 0.87%	205,245 3.05%	80,396 -	6,663,547 99.02%	66,277 0.98%	80,396 -	Carried
2e.	Ratification of Prior Issue of Shares - Issue of Shares to Lind (31 December 2024)	Ordinary	6,376,013 94.86%	140,644 2.09%	205,245 3.05%	80,396 -	6,581,258 97.79%	148,566 2.21%	80,396 -	Carried
2f.	Ratification of Prior Issue of Shares - Issue of Shares to Lind (23 January 2025)	Ordinary	6,376,013 94.86%	140,644 2.09%	205,245 3.05%	80,396 -	6,581,258 97.79%	148,566 2.21%	80,396 -	Carried

Resolution Details			Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Results
Resolution		Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
3a.	Ratification of Prior Issue of Options - Issue of Options to Vendors (27 November 2024)	Ordinary	6,482,938 96.46%	32,401 0.48%	118,152 1.76%	81,534 -	6,601,090 99.44%	37,401 0.56%	81,534 -	Carried
3b.	Ratification of Prior Issue of Options - Issue of Options to Vendors (13 January 2025)	Ordinary	6,476,269 96.36%	33,451 0.50%	123,771 1.84%	81,534 -	6,602,962 99.38%	41,373 0.62%	81,534 -	Carried
4.	Ratification of Issue of Tranche 1 Placement	Ordinary	6,322,610 95.94%	61,720 0.94%	205,425 3.12%	51,000 -	6,528,035 98.94%	69,642 1.06%	51,000 -	Carried
5.	Approval to Issue Tranche 2 Placement	Ordinary	6,461,267 96.00%	63,771 0.95%	205,425 3.05%	51,000 -	6,666,692 98.94%	71,693 1.06%	51,000 -	Carried
6.	Approval to Issue Placement Options	Ordinary	6,318,421 95.91%	63,771 0.97%	205,425 3.12%	53,138 -	6,523,846 98.91%	71,693 1.09%	53,318 -	Carried

\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.